In a groundbreaking Canadian clinical trial, researchers have discovered that Tenecteplase (TNK), a drug typically employed as a clot-buster for heart attacks, can be a safe and efficient treatment for acute ischemic stroke. Brian Buck, a neurology professor at the University of Alberta’s Faculty of Medicine & Dentistry and a co-author of the study, clarified that ischemic strokes occur when an artery becomes blocked.

The trial demonstrated that this innovative treatment could cut the death rate from major ischemic strokes by 50% and decrease stroke-related disabilities. Dr. Michael Hill, the study’s senior author and a professor at the University of Calgary’s Cumming School of Medicine, declared, “This is the most significant and fundamental change in acute ischemic stroke treatment in the last 20 years. These results will impact stroke care around the world.”

Published in ‘The Lancet,’ the study suggests that “Intravenous tenecteplase (0·25 mg/kg) is a reasonable alternative to alteplase for all patients presenting with acute ischemic stroke who meet standard criteria for thrombolysis.” Dr. Bijoy Menon, the study’s co-principal investigator, expressed that the trial’s findings are “truly important” and have the potential to “revolutionize stroke treatment throughout the world.”

Menon further elaborated, “Tenecteplase is known to be an effective clot dissolving drug. It is very easy to administer, which makes it a game changer when seconds count to save brain cells.”

Medical Express reported that Alteplase (tPA), the currently recommended drug for stroke patients, has its drawbacks, such as being more complicated to administer and requiring an infusion pump that needs monitoring. This can create difficulties when transporting patients within hospitals or major stroke centers for treatment.

In contrast, tenecteplase can be given as a single immediate dose, according to Dr. Rick Swartz. “That’s a big advantage, saving critical time and complication. TNK could potentially be administered wherever the patient is seen first, at a medical center or small hospital,” Swartz said.

Brian Buck, in statements shared by The Daily Wire, emphasized that tenecteplase can be given in a single bolus of drug in under a minute, wherever the patient is initially seen, and without necessitating an infusion pump. This is advantageous for mobile stroke units, as it enables the crew to focus on transporting the patient to the hospital.

Buck said, “Going forward, tenecteplase will be an important medical therapy that will hopefully be available to Albertans who are suffering from an ischemic stroke.”

Furthermore, the University of Alberta reported that the researchers devised a straightforward consent and enrollment process that incorporated a mobile app, enabling them to quickly and safely register patients.

Buck stated, “This was important during the peak of COVID since it was essential to minimize return visits to the hospital and contact between study patients and staff.”

WATCH the video below for more details:

Sources: ThegoptimesDailyWire

Leave a Reply

Your email address will not be published.